Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.
I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.
The company’s pipeline includes several promising candidates:
- Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
- Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
- Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
- Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
- Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).
I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.
Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.
For the latest updates and detailed information, visit the official website at I-Mab Biopharma.
I-Mab (Nasdaq: IMAB), a biopharmaceutical company, announced its participation in several healthcare conferences in November 2021. Notable events include the Goldman Sachs Asia Pacific Healthcare Forum, Jefferies London Healthcare Conference, BioCentury-BayHelix China Healthcare Summit, Morgan Stanley Asia Pacific Summit, and Piper Sandler Healthcare Conference. Key management personnel, including Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, will represent the company in various discussions. I-Mab's focus remains on advancing its innovative pipeline in immuno-oncology and autoimmune diseases.
I-Mab (Nasdaq: IMAB) has announced the appointment of John Long as Chief Financial Officer and Jielun Zhu as Chief Strategy Officer, effective immediately. These appointments are aimed at enhancing I-Mab's executive leadership as it transitions into a global biopharma company. Long brings over 20 years of financial management experience, while Zhu, the former CFO, will focus on strategic corporate development. The company is advancing its commercialization plans for late-stage assets, promising growth opportunities.
I-Mab has formed a strategic partnership with Sinopharm to enhance its commercial capabilities in China. The collaboration grants over 300 Sinopharm subsidiaries authorization as distributors, aiming to streamline the go-to-market process for I-Mab's innovative therapies. I-Mab is on track to submit its Biologics License Application (BLA) for a third-line multiple myeloma treatment in Q4 2021. This partnership supports I-Mab's goal of transitioning to a fully integrated biopharmaceutical company with robust manufacturing and commercialization capabilities.
I-Mab (Nasdaq: IMAB) is expanding its U.S. operations by establishing a new R&D site in San Diego, aimed at enhancing its global drug development capabilities. This site will complement its existing facility in Gaithersburg, Maryland, forming an integrated U.S. R&D center that supports clinical studies across China and the U.S. The company aims to attract top talent and invest significantly over the next two years, focusing on immuno-oncology and translational medicine, to advance its innovative pipeline of over 20 assets.
I-Mab (Nasdaq: IMAB) announced the approval of its IND submission for a phase 2 clinical trial of efineptakin alfa in combination with PD-1 therapy for patients with advanced solid tumors, including triple-negative breast cancer and head and neck cancers. Efineptakin alfa is a long-acting recombinant human interleukin-7 aimed at boosting T lymphocytes for cancer treatment. Previous studies indicated its safety and efficacy, significantly increasing T-cell numbers and achieving a notable overall response rate in metastatic TNBC. The trial initiation represents a significant step in advancing I-Mab's innovative pipeline.
I-Mab (NASDAQ: IMAB) has completed patient enrollment for its phase 3 trial of felzartamab, a human CD38 antibody, in combination with lenalidomide for second-line treatment of multiple myeloma (MM). The trial aims to evaluate progression-free survival compared to lenalidomide and dexamethasone. The company plans to submit a Biologics License Application (BLA) for this treatment in Q4 2021. Additionally, an IND application for felzartamab in combination with another asset for first-line treatment is also scheduled for Q4 2021.
On October 5, 2021, I-Mab (Nasdaq: IMAB) and ABL Bio announced the upcoming presentation of preclinical data for two bispecific antibodies, TJ-CD4B/ABL111 and TJ-L14B/ABL503, at the Society for Immunotherapy of Cancer's Annual Meeting from November 12-14, 2021. TJ-CD4B/ABL111, targeting Claudin18.2 in gastric and pancreatic cancers, is in Phase 1 trials in the U.S. TJ-L14B/ABL503, designed to enhance anti-tumor activity while minimizing toxicity, is also in Phase 1 trials. The announcement underscores I-Mab's commitment to advancing innovative therapies in cancer treatment.
I-Mab (Nasdaq: IMAB) announced its participation in two upcoming conferences in October. The J.P. Morgan Global Healthcare Conference, held from October 12-13 in Shanghai, and the virtual Jefferies China Biotech Summit on October 26, 2021, will feature key management personnel including the founder and CEO. I-Mab focuses on the development of innovative biologics, particularly in immuno-oncology, and is transitioning towards becoming a fully integrated global biopharmaceutical company with extensive R&D and manufacturing capabilities.
I-Mab (Nasdaq: IMAB) announced significant clinical advancements for its anti-CD47 monoclonal antibody, lemzoparlimab. The phase 2 trial for non-Hodgkin's lymphoma (NHL) is now multi-centered, including sites in China, with preliminary data submitted for the ASH 2021 presentation. Concurrently, the AML/MDS trial is on track for patient enrollment completion by Q4 2021. Furthermore, the NMPA has approved a phase 2 trial for lemzoparlimab combined with toripalimab for advanced solid tumors. These advancements position I-Mab favorably for upcoming registrational trials in China.
I-Mab (Nasdaq: IMAB) announced that China's NMPA has accepted its IND application to initiate a Phase 2 trial for enoblituzumab combined with pembrolizumab (Keytruda®) in patients with selected solid tumors. This trial aims to evaluate the efficacy of enoblituzumab, a monoclonal antibody targeting B7-H3, which is linked to poor cancer prognosis. Data from previous studies suggest potential positive treatment outcomes. The trial, involving cancers like non-small cell lung cancer (NSCLC) and urothelial carcinoma, leverages prior clinical data from MacroGenics to expedite development in Greater China.
FAQ
What is the current stock price of I-MAB American Depositary Shares (IMAB)?
What is the market cap of I-MAB American Depositary Shares (IMAB)?
What is I-Mab's core focus?
What are some key products in I-Mab's pipeline?
Where are I-Mab's main operations located?
What recent strategic move has I-Mab made?
What is felzartamab?
Who is I-Mab collaborating with on givastomig?
How does I-Mab fund its operations and research?
What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?
What is I-Mab's approach to drug development?
How can investors stay updated on I-Mab's progress?
